자궁경부 이형성 시장 : 유형별, 진단·치료별, 최종사용자별 - 세계 예측(2024-2032년)

Cervical Dysplasia Market size is set to record 7.1% CAGR from 2024 to 2032 due to the growing partnerships along with advancements in treatment options.

Medical researchers and healthcare providers are working together to enhance diagnostic methods and develop more effective treatments for cervical dysplasia. These collaborative efforts are driving the progress of innovative therapies and improving patient care. With the expanding partnerships and new treatment options becoming available, the management of cervical dysplasia is evolving to include more personalized and targeted approaches. For instance, in April 2024, BD announced a strategic partnership with Healthians to enhance cervical cancer screening while offering women an innovative option for self-collecting samples at home to improve early detection of cervical dysplasia.

The cervical dysplasia industry is segmented into type, diagnosis and treatment, end-user, and region.

The market share from the high-grade cervical dysplasia type segment will record a decent growth rate between 2024 and 2032. High-grade cervical dysplasia is characterized by significant alterations in cervical cells that have a higher risk of progressing to cervical cancer if left untreated. The growing focus of medical professionals on monitoring and diagnosing this type of dysplasia to ensure early intervention and effective management will add to the segment growth.

In terms of end-user, the cervical dysplasia market size from the diagnostic centers segment is anticipated to witness significant CAGR from 2024-2032. This is driven by rising adoption for identifying and managing cervical dysplasia. These centers are offering advanced screening and diagnostic services including Pap smears, HPV tests, and colposcopies to detect abnormal cell changes in the cervix. Moreover, diagnostic centers are integrating more advanced technologies, such as next-generation sequencing and enhanced imaging techniques to further refine the disease detection and management.

Asia Pacific cervical dysplasia industry size will record significant CAGR through 2032 due to the growth in women health services and supportive government programs. Government initiatives are promoting preventive care and providing resources for early detection, further driving greater awareness and access to necessary services. This support is also improving early detection rates and treatment outcomes, ultimately contributing to better management of cervical dysplasia and overall women health in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of cervical dysplasia
    • 3.2.1.2 Expanding R&D funding and activities
    • 3.2.1.3 Growing awareness and diagnosis
    • 3.2.1.4 Improved diagnostic technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and adverse reactions
    • 3.2.2.2 Regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 High-grade cervical dysplasia
• 5.3 Low-grade cervical dysplasia

Chapter 6 Market Estimates and Forecast, By Diagnosis and Treatment, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Diagnosis
  • 6.2.1 Pap smear test
  • 6.2.2 HPV DNA test
  • 6.2.3 Colposcopy
  • 6.2.4 Biopsy
  • 6.2.5 Other diagnosis tests
• 6.3 Treatment
  • 6.3.1 Surgical treatment
    • 6.3.1.1 Loop electrosurgical excision procedure (LEEP)
    • 6.3.1.2 Cold knife conization (CKC)
    • 6.3.1.3 Cryosurgery
    • 6.3.1.4 Other surgical treatments
  • 6.3.2 Non-surgical treatment
    • 6.3.2.1 Topical medications
    • 6.3.2.2 Immunotherapy

Chapter 7 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Diagnostic centers
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Asieris Pharmaceuticals
• 9.3 Becton, Dickinson and Company
• 9.4 F. Hoffmann-La Roche Ltd.
• 9.5 GlaxoSmithKline PLC
• 9.6 Hologic Inc.
• 9.7 Kinopharma
• 9.8 Merck & Co., Inc.
• 9.9 OncoHealth Corporation
• 9.10 Qiagen